Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Action inhibitors |
Mechanism ITGB6 inhibitors(integrin subunit beta 6 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of Esophagus | Phase 1 | - | 07 Aug 2025 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 1 | - | 07 Aug 2025 | |
Advanced Malignant Solid Neoplasm | Phase 1 | - | 07 Aug 2025 | |
Bladder Cancer | Phase 1 | - | 07 Aug 2025 | |
Esophageal Squamous Cell Carcinoma | Phase 1 | - | 07 Aug 2025 | |
Gastroesophageal junction adenocarcinoma | Phase 1 | - | 07 Aug 2025 | |
Pancreatic adenocarcinoma | Phase 1 | - | 07 Aug 2025 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | - | 07 Aug 2025 | |
Urothelial Carcinoma of the Urinary Bladder | Phase 1 | - | 07 Aug 2025 | |
Non-Small Cell Lung Cancer | Preclinical | United States | 28 Apr 2025 |